Aqueous fraction of beta vulgaris ameliorates hyperglycemia in diabetic mice due to enhanced glucose stimulated insulin secretion, mediated by acetylcholine and GLP-1, and elevated glucose uptake via increased membrane bound GLUT4 transporters

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Kabir, Ashraf Ul ^a   Samad, Mehdi Bin ^a   Ahmed, Arif ^a   Jahan, Mohammad Rajib ^a   Akhter, Farjana ^a   Tasnim, Jinat ^a   Nageeb Hasan, S M ^a   Sayfe, Sania Sarker ^b   Hannan, J M A ^a  

^a NORTH SOUTH UNIVERSITY   (Bangladesh)

^b KHULNA UNIVERSITY   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANTIDIABETIC AGENT; ATROPINE; BETA VULGARIS EXTRACT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXTENDIN 9; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE 6 PHOSPHATE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE; HEMICHOLINIUM 3; HEXOKINASE; HEXOKINASE II; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; PANCREAS POLYPEPTIDE; PHOSPHOLIPASE C; PHYSOSTIGMINE; PLANT EXTRACT; RECEPTOR BLOCKING AGENT; SAXAGLIPTIN; SOMATOMEDIN C; SOMATOSTATIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VESAMICOL; GLYCOGEN; INSULIN; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BEET; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLYCOGEN MUSCLE LEVEL; GLYCOGEN SYNTHESIS; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MOLECULAR DYNAMICS; MOUSE; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PANCREAS ISLET; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SKELETAL MYOCYTE; ANIMAL; CELL MEMBRANE; CHEMISTRY; COMPLICATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HOMEOSTASIS; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; SECRETION (PROCESS); TRANSPORT AT THE CELLULAR LEVEL;

ANIMALIA; BETA VULGARIS; MUS;

ACETYLCHOLINE; ANIMALS; BETA VULGARIS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; GLUCOSE-6-PHOSPHATE; GLYCOGEN; GLYCOGEN SYNTHASE; HEXOKINASE; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN; MICE; MUSCLE CELLS; MUSCLE, SKELETAL; PLANT EXTRACTS; WATER;

EID: 84922356798     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116546     Document Type: Article

References (54)

1. Yanarda G R, Çolak H (1998) Effect of Chard (Beta vulgaris L. var. cicla) on Blood Glucose Levels in Normal and Alloxan-induced Diabetic Rabbits. Pharmacy and pharmacology communications 4: 309-311.
2. Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K (2002) The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes care 25: 608-613. PMID: 11874956
3. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, et al. (2008) Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes care 31: S61-S78.
4. Bolkent Ş, Yanardaʇ R, Tabakoʇlu-Oʇuz A, Özsoy-Saçan Ö (2000) Effects of chard (Beta vulgaris L. var. cicla) extract on pancreatic B cells in streptozotocin-diabetic rats: a morphological and biochemical study. Journal of ethnopharmacology 73: 251-259.
5. Yanardaʇ R, Bolkent Ş, Özsoy-Saçan Ö, Karabulut-Bulan Ö (2002) The effects of chard (Beta vulgaris L. var. cicla) extract on the kidney tissue, serum urea and creatinine levels of diabetic rats. Phytotherapy Research 16: 758-761. PMID: 12458482
6. Yarat A, ÖZÇElik F, Yanardag R, Tunali T, ÖZsoy Ö, et al. (1998) The Effect of Chard (Beta vulgaris L. var. cicla) on the Protein and Antioxidant Systems in Lenses of Streptozotocin-induced Diabetic Rats. Pharmacy and Pharmacology Communications 4: 271-274.
7. Sener G, Saçan Ö, Yanardag R, Ayanoglu-Dülger G (2002) Effects of chard (Beta vulgaris L. var. cicla) extract on oxidative injury in the aorta and heart of streptozotocin-diabetic rats. Journal of medicinal food 5: 37-42. PMID: 12511111
8. Escribano J, Pedreño MA, García-Carmona F, Muñoz R (1998) Characterization of the antiradical activity of betalains from Beta vulgaris L. roots. Phytochemical Analysis 9: 124-127.
9. Hannan JMA, Ali L, Khaleque J, Akhter M, Flatt PR, et al. (2012) Antihyperglycaemic activity of Asparagus racemosus roots is partly mediated by inhibition of carbohydrate digestion and absorption, and enhancement of cellular insulin action. British Journal of Nutrition 107: 1316-1323. doi: 10.1017/ S0007114511004284 PMID: 21899804
10. Bayne K (1996) Revised Guide for the Care and Use of Laboratory Animals available. American Physiological Society. The Physiologist 39: 199, 208. PMID: 8854724
11. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J (2008) Evaluating the glucose tolerance test in mice. American Journal of Physiology-Endocrinology and Metabolism 295: E1323-E1332. PMID: 18812462
12. Trinder P (1969) Glucose GOD-PAP method enzymatic colorimetric method. Ann Clin Biochem 6:24. PMID: 12481676
13. Li D-S, Yuan Y-H, Tu H-J, Liang Q-L, Dai L-J (2009) A protocol for islet isolation from mouse pancreas. Nature protocols 4: 1649-1652. PMID: 19876025
14. Prentki M, Matschinsky FM (1987) Ca2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiol Rev 67: 1185-1248. PMID: 2825225
15. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157.
16. Klip A, Ramlal T, Young DA, Holloszy JO (1987) Insulin-induced translocation of glucose transporters in rat hindlimb muscles. FEBS letters 224: 224-230. PMID: 2960560
17. Baron AD, Zhu JS, Zhu JH, Weldon H, Maianu L, et al. (1995) Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. Journal of Clinical Investigation 96:2792. PMID: 8675649
18. Danforth WH (1965) Glycogen synthetase activity in skeletal muscle interconversion of two forms and control of glycogen synthesis. Journal of Biological Chemistry 240: 588-593.
19. Porte D Jr (1967) A receptor mechanism for the inhibition of insulin release by epinephrine in man. Journal of Clinical Investigation 46:86. PMID: 6018752
20. Loubatieres-Mariani MM, Chapal J, Alric R, Loubatieres A (1973) Studies of the cholinergic receptors involved in the secretion of insulin using isolated perfused rat pancreas. Diabetologia 9: 439-446. PMID: 4589822
21. Malaisse WJ, Sener A, Herchuelz A, Hutton JC (1979) Insulin release: the fuel hypothesis. Metabolism 28: 373-386.
22. Fehmann H-C, Arnold R, Goke B (1989) Signal transmission after GLP-I (7-36) amide binding in RINm5F cells.
23. Prentki M, Matschinsky FM, Madiraju SR (2013) Metabolic signaling in fuel-induced insulin secretion. Cell metabolism 18: 162-185. PMID: 23791483
24. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, et al. (1993) Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. American journal of hypertension 6: 260S-270S. PMID: 8398010
25. Klein R, Klein BEK, Moss SE, Cruickshanks KJ (1994) Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Archives of internal medicine 154: 2169-2178. PMID: 7944837
26. Klein R (1995) Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes care 18: 258-268. PMID: 7729308
27. Boulton AJM, Malik RA (1998) Diabetic neuropathy. Medical Clinics of North America 82: 909-929.
28. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R (1998) Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Archives of internal medicine 158: 998-004. PMID: 9588433
29. Monnier L, Mas E, Ginet C, Michel F, Villon L, et al. (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Jama 295: 1681-1687. PMID: 16609090
30. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, et al. (2002) Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. The Journal of Clinical Endocrinology & Metabolism 87: 978-982. PMID: 11889147
31. Gerich JE (2003) Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Archives of internal medicine 163: 1306-1316. PMID: 12796066
32. Rubin RJ, Altman WM, Mendelson DN (1994) Health care expenditures for people with diabetes mellitus, 1992. The Journal of Clinical Endocrinology & Metabolism 78: 809A-809F. PMID: 8157701
33. Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, et al. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). lancet 352: 837-853.
34. Bolen S, Feldman L, Vassy J, Wilson L, Yeh H-C, et al. (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of internal medicine 147: 386-399. PMID: 17638715
35. Franz MJ, Monk A, Barry B, McClain K, Weaver T, et al. (1995) Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. Journal of the American Dietetic Association 95: 1009-1017. PMID: 7657902
36. Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiological research 50: 537-546. PMID: 11829314
37. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E (1997) Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes care 20: 1353-1356. PMID: 9283777
38. Honey RN, Weirf GC (1980) Acetylcholine Stimulates Insulin, Glucagon, and Somatostatin Release in the Perfused Chicken Pancreas∗. Endocrinology 107: 1065-1068. PMID: 6105951
39. Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Journal of Clinical Investigation 79:616. PMID: 3543057
40. Henquin J-C (2000) Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49: 1751-1760. PMID: 11078440
41. Duttaroy A, Zimliki CL, Gautam D, Cui Y, Mears D, et al. (2004) Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice. Diabetes 53: 1714-1720. PMID: 15220195
42. Rasmussen H, Zawalich KC, Ganesan S, Calle R, Zawalich WS (1990) Physiology and pathophysiology of insulin secretion. Diabetes Care 13: 655-666.
43. Nauck M, Kleine N, Ørskov C, Holst JJ, Willms B, et al. (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744. PMID: 8405741
44. Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, et al. (2007) Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes care 30: 1608-1610. PMID: 17372153
45. Parks M, Rosebraugh C (2010) Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. New England Journal of Medicine 362: 774-777. doi: 10.1056/NEJMp1001578 PMID: 20164475
46. Wang Q, Li L, Xu E, Wong V, Rhodes C, et al. (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47: 478-487. PMID: 14762654
47. DeFronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of NIDDM: a balanced overview. Diabetes care 15: 318-368.
48. Morgan HE, Henderson MJ, Regen DM, Park CR (1961) Regulation of glucose uptake in muscle. J Biol Chem 236: 253-261.
49. Evans DJ, Murray R, Kissebah AH (1984) Relationship between skeletal muscle insulin resistance, insulin- mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography. Journal of Clinical Investigation 74:1515. PMID: 6148358
50. Baron AD, Brechtel G, Wallace P, Edelman SV (1988) Rates and tissue sites of non-insulin-and insulinmediated glucose uptake in humans. American Journal of Physiology-Endocrinology And Metabolism 255: E769-E774. PMID: 3059816
51. Kraegen EW, Sowden JA, Halstead MB, Clark PW, Rodnick KJ, et al. (1993) Glucose transporters and in vivo glucose uptake in skeletal and cardiac muscle: fasting, insulin stimulation and immunoisolation studies of GLUT1 and GLUT4. Biochem j 295: 287-293. PMID: 8216230
52. Zisman A, Peroni OD, Abel ED, Michael MD, Mauvais-Jarvis F, et al. (2000) Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nature medicine 6: 924-928. PMID: 10932232
53. Koranyi LI, Bourey RE, Vuorinen-Markkola H, Koivisto VA, Mueckler M, et al. (1991) Level of skeletal muscle glucose transporter protein correlates with insulin-stimulated whole body glucose disposal in man. Diabetologia 34: 763-765. PMID: 1959709
54. Villar-Palasi C, Guinovart JJ (1997) The role of glucose 6-phosphate in the control of glycogen synthase. The FASEB journal 11: 544-558.